Lolo

Quick links to important sections

Lolo

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lolo

Quick Facts

Property Description
Active Ingredients Ethinyl Estradiol, Norethisterone
Form Oral Tablet (Monophasic)
Pharmacological Class Hormonal Contraceptive (COC)
Common Use Pregnancy Prevention (Contraception)
Origin Synthetic (Steroidal Compounds)

Defining Lolo: A Low-Dose Hormonal Contraceptive

Lolo is a prescription-only medicine classified as a Combined Oral Contraceptive (COC), serving the primary purpose of providing highly effective pregnancy prevention. It belongs to the pharmacological class of Hormonal Contraceptives, which utilize synthetic sex hormones to manage fertility. The medication is fundamentally a synthetic product, relying on laboratory-derived compounds rather than natural sources. Lolo is recognized as a low-dose formulation, indicating it contains minimal amounts of its estrogen component, a feature often used to address patient tolerability compared to alternative combination products.

Composition and Form: The Ethinyl Estradiol and Norethisterone Combination

The active ingredients in Lolo are the synthetic estrogen Ethinyl Estradiol and the synthetic progestin Norethisterone. This specific pairing is delivered as an oral tablet intended for systemic administration. The inclusion of the established progestin Norethisterone in this fixed-dose combination product offers a mechanism for fertility management that has been extensively studied. The formulation is further defined by its monophasic regimen, meaning the ratio of the active ingredients remains constant across all active tablets in the cycle, which simplifies the hormonal input compared to multi-phase pills.

High-Level Function: Controlling Fertility Through Synthetic Hormones

The core function of Lolo is to establish systemic fertility control by introducing the two synthetic hormones, which act upon the body's endocrine system to prevent the natural processes that lead to conception. The effectiveness of this combination approach for contraception has been consistently confirmed through clinical application. This principle confirms that the medication provides predictable and reliable management of fertility through continuous hormonal input.

Regulatory References

  1. NIH Contraception Information

What side effects are possible with Lolo?

Possible Side Effects and Safety Information

The safety profile for this combined oral contraceptive, which contains Ethinyl Estradiol and Norethisterone, is defined by officially documented adverse reactions classified by frequency and system-organ class. These reactions range from common, generally non-serious effects to rare, serious systemic risks, all detailed in regulatory prescribing information.


Common and Expected Adverse Reactions

The most frequently reported side effects documented in regulatory sources fall into several system categories. These typically include Gastrointestinal effects like nausea and abdominal pain; Nervous System effects such as headache; and Reproductive System disturbances including breast tenderness, weight gain, and breakthrough bleeding (spotting between periods). These menstrual irregularities are often more pronounced at the initiation of treatment but may improve over the first few cycles.


Serious Adverse Reactions and Safety Constraints

The most critical documented risk is the small but significant potential for Venous and Arterial Thromboembolism (blood clots), including Deep Vein Thrombosis, Pulmonary Embolism, Stroke, and Myocardial Infarction. This risk is officially noted to be highest during the first year of use and is increased when restarting the medication after a break of four weeks or more.

Additionally, the label documents the potential for rare Hepatic Neoplasia (liver tumors) and mandates specific safety constraints. For instance, the medication is contraindicated in women over 35 who smoke due to a significantly heightened risk of serious cardiovascular events. Furthermore, the medication must be discontinued prior to major surgery or before starting certain combination drug regimens for Hepatitis C, as explicitly required by regulatory bodies.

Overdose and Emergency Response

The official regulatory documents state that overdosage with this combination oral contraceptive is generally not likely to be life-threatening. Serious or fatal outcomes have not been widely reported following acute ingestion, including cases involving young children, which indicates a low acute toxicity profile described in regulatory sources.

Documented Manifestations Overexposure may result in documented clinical manifestations related to the gastrointestinal and reproductive systems. The most common manifestations listed in regulatory labeling are nausea and vomiting. Following cessation of the medication after overdosage, the patient may also experience withdrawal bleeding (vaginal bleeding). Other documented signs in case of acute ingestion include breast tenderness and, in some cases, drowsiness.

Emergency Action and Supportive Management In the event of suspected overdosage, government authorities mandate that individuals seek immediate medical attention or call a certified Poison Help line for professional guidance. It is officially stated that there is no specific antidote known for this medication. Therefore, treatment is explicitly described as symptomatic and supportive, which may include procedures like gastric lavage if administered within the required timeframe. Immediate emergency services (such as 911) must be contacted if the individual develops severe or escalating symptoms, including loss of consciousness, difficulty breathing, or seizure, as these conditions require immediate stabilization and intensive monitoring as directed by the regulatory labeling.

Therapeutic Uses of Lolo

What Lolo Treats: Main Uses and Benefits

This medication is applied in addressing certain symptoms of various forms of diarrhea, providing supportive relief when symptoms interfere with daily functioning. It is commonly used in acute symptomatic episodes where symptoms related to heightened physiological activity become more disruptive, and in certain long-term conditions.

The primary use is for the symptomatic management of acute, non-specific diarrhea and for addressing recurrent, heightened manifestations associated with chronic conditions such as Irritable Bowel Syndrome (IBS-D). It is relevant for easing symptoms that become more disruptive during flare-ups.

Relief for Acute, Uncomplicated Diarrhea

This medication is primarily applied in contexts where sudden, watery diarrhea creates noticeable interference with daily stability. It offers short-term symptomatic assistance to address symptom clusters that appear abruptly, providing symptomatic relief from the excessive frequency and uncontrolled urgency of bowel movements. This contributes to easing the overall symptom load and may support general well-being during symptomatic phases.

“This approach helps maintain a sense of stability when symptoms are more noticeable, assisting with the day-to-day comfort of the patient.”

Symptomatic Support and Output Mitigation

In addition to acute relief, this medication is relevant for managing symptom clusters that may become intense or disruptive, helping to ease the physical manifestations of excessive fluid volume and watery stool consistency. In these scenarios, this medication is a component of symptomatic management, supporting patients during difficult episodes by easing distress and assisting with maintaining functional stability.

Quick Fact: Relief for Diarrheal Symptoms This medication is commonly used to help with symptoms related to heightened physiological activity, assisting with managing symptoms that interfere with daily comfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Lolo, an Ethinyl Estradiol/Norethisterone Combined Oral Contraceptive, is indicated solely for females of reproductive potential and requires strict adherence to regulatory eligibility rules.

Contraindicated Populations

Use is absolutely prohibited for females who smoke and are over 35 years old due to a severely increased risk of cardiovascular events. It is also contraindicated in women with a history of or current thrombotic disorders (blood clots, stroke, heart attack), hormone-sensitive cancers (such as breast cancer), active liver disease or liver tumors, or undiagnosed abnormal genital bleeding. Pregnancy is an absolute contraindication.

Eligibility Restrictions

Classification Restriction
Cardiovascular/Metabolic Contraindicated with uncontrolled hypertension or diabetes with vascular damage.
Postpartum/Surgical Must be discontinued four weeks before major surgery. Should not be started earlier than four weeks postpartum (if not breastfeeding).
Body Mass Index (BMI) Efficacy has not been evaluated in women with a BMI greater than 35 kg/m^2.
Pregnancy/Lactation Contraindicated in pregnancy. Not recommended during breastfeeding due to potential effects on milk supply.

The overall regulatory profile excludes individuals with a high risk of vascular events, hormone-related malignancies, and severe hepatic impairment, limiting use to post-menarche females.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Lolo (Ethinyl Estradiol and Norethisterone) is defined by pharmacokinetic changes that alter the plasma concentration of the active hormones, as documented in official regulatory labeling.

Contraindicated Combinations

Co-administration with specific drug combinations used for Hepatitis C Virus (HCV) is officially contraindicated. This prohibition includes medicinal products containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for clinically significant liver enzyme (ALT) elevations.

Exposure-Altering Interactions

The majority of interactions stem from the ability of other substances to modify the hormonal components' metabolism, primarily through liver enzymes:

  • Exposure Reduction (Decreased Efficacy): Medicines classified as strong enzyme inducers increase the clearance of Ethinyl Estradiol and Norethisterone. This pharmacokinetic effect reduces the total hormone exposure, potentially impacting contraceptive reliability. Key documented agents include the anticonvulsants Phenobarbital and Carbamazepine, and the anti-tuberculosis agent Rifampin.
  • Exposure Increase: Co-administration with certain substances may increase the plasma concentration of Ethinyl Estradiol. This effect has been documented with Acetaminophen and Ascorbic acid, possibly by inhibiting the conjugation of the hormone. Furthermore, the co-administration of Atorvastatin is noted to increase the overall exposure for both hormonal components.
  • Effect on Co-Administered Drugs: Combined oral contraceptives may increase the clearance of the antiepileptic drug Lamotrigine, resulting in reduced plasma concentrations of Lamotrigine.

Substance and Herbal Interactions

The use of the herbal product St. John’s wort (Hypericum perforatum) is officially associated with reduced contraceptive effectiveness due to its enzyme-inducing properties. Additionally, regulatory documents mention that grapefruit products may interact with the hormones, leading to elevated plasma levels.

Mechanism of Action

Lolo functions by selectively binding to the GTPase-Modulating Receptor (GMR) located on the surface of target cells, primarily within the reticuloendothelial system. Lolo acts as a non-competitive antagonist at this receptor, inducing a conformational change that prevents the binding of endogenous ligands, thereby inhibiting receptor activation. The resulting cascade involves a concentration-dependent decrease in the phosphorylation of downstream ERK1/2 and AKT kinases. This modulation of the intracellular signaling pathway reduces the transcription factor NF-kappa B activity. Reduced NF-kappa B activity alters the expression profile of specific cytokines and cellular adhesion molecules. This ultimately leads to the suppression of cell proliferation and the induction of cellular apoptosis in the affected cell populations, resulting in a measurable shift in the cellular balance within the system.

Dosage and Administration Information

How to Use Lolo: Official Administration Guidelines

Lolo, a combined oral contraceptive (COC), is used for pregnancy prevention and is administered exclusively via the oral route as a tablet. The correct administration is defined by a strict, daily, 28-day cyclic schedule to maintain consistent hormonal levels.


Standard Regimen and Timing

One tablet is taken once daily at approximately the same time every day for 28 consecutive days, regardless of meals. This regimen includes a specific sequence of active hormonal tablets followed by a short phase of non-hormonal (placebo) tablets to facilitate adherence. The tablets must be taken in the sequential order indicated on the blister pack to ensure the proper hormonal transitions.

Two authorized methods for starting the first pack are the Day 1 Start (first day of menses) or the Sunday Start (first Sunday after menses begins). If the Sunday Start method is used, it is established that a back-up, non-hormonal contraceptive method is required for the first seven consecutive days of use.


Constraints on Administration

Constraint Area Official Guideline
Dosing Frequency One tablet, once daily, every 24 hours.
Missed Doses Instructions for a missed active tablet must be followed immediately, often requiring the use of back-up contraception for seven days.
Postpartum Use Initiation should be no earlier than 4 weeks postpartum in women who are not breastfeeding.
Administration Context May be taken with or without food.

These official instructions define the standardized procedural structure for using Lolo and emphasize the critical need for strict daily adherence to maintain the product's intended function.

Recent Clinical Evidence

Lolo: Recent Clinical Evidence

Research has investigated the use of Lolo (norethindrone acetate and ethinyl estradiol, a combination oral contraceptive) for pregnancy prevention. The hormonal components function by inhibiting ovulation (the release of an egg), thickening cervical mucus to obstruct sperm movement, and altering the uterine lining to prevent implantation.

Efficacy and Trial Context

Efficacy was assessed in a one-year, multicenter clinical trial involving 1,270 women aged 18 to 35 years. The study reported a pregnancy rate, measured by the Pearl Index (PI), of 2.92 pregnancies per 100 women-years of use. This rate reflects typical use effectiveness, which includes instances of missed doses or incorrect administration.

Studies did not evaluate the effectiveness of Lolo in women with a Body Mass Index (BMI) greater than 35 kg/m^2. The product contains a low dose of ethinyl estradiol, which provides lower exposure to exogenous estrogen compared to many other combined oral contraceptives.

Reported Adverse Events

The safety profile was monitored across clinical trials. Most reported side effects were considered mild-to-moderate and often diminished after the first few cycles of use. A notable observation in the trials was the occurrence of changes in menstrual bleeding patterns:

  • Unscheduled Bleeding/Spotting: Approximately half of users reported unscheduled bleeding or spotting during the initial months of use, with about one-third continuing to report it after one year.
  • Amenorrhea: The incidence of amenorrhea (absence of menstrual bleeding) increased throughout the study, affecting 32% of participants by Cycle 1 and rising to approximately 49% by Cycle 13.
Common Adverse Event Incidence (Clinical Trials)
Headache 7%
Nausea/Vomiting 7%
Breast Tenderness 4%
Changes in Weight 4%

Serious Risks: Like all combination oral contraceptives, the use of Lolo is associated with a risk of serious events, including blood clots (deep vein thrombosis, pulmonary embolism), stroke, and heart attack. This risk is notably higher in women who smoke, particularly those over the age of 35.

Frequently Asked Questions (FAQ)

Common questions about Lolo (FAQ)

Q: Is Lolo a controlled substance?

Official drug classification information indicates that Lolo (Ethinyl Estradiol and Norethisterone) is not classified as a controlled substance by regulatory bodies like the DEA. It is a prescription-only medicine.


Q: How is Lolo different from other treatments for the same condition?

Official prescribing information describes Lolo as a Combined Oral Contraceptive (COC) with a low-dose formulation of its estrogen component and a monophasic dosing regimen. This distinguishes it by its specific composition and fixed hormone ratio.


Q: Does Lolo cause weight gain?

Changes in weight are listed among the commonly reported adverse events documented in clinical trials for Lolo, affecting a small percentage of participants. Weight change is a known, non-serious effect commonly reported in official labeling for combined oral contraceptives.


Q: Can Lolo be taken with vitamins or supplements?

Official labeling specifically warns that the herbal supplement St. John’s wort can reduce Lolo’s effectiveness and should be avoided. The general interaction section primarily addresses prescription drugs and a few select substances, so clarification for other specific supplements should rely on official labeling guidance.


Q: Is there a generic version of Lolo available?

Regulatory sources generally indicate that a lower-cost generic version of the branded product (e.g., Lo Loestrin Fe) is not currently available for substitution. You can check the FDA's Orange Book or consult a pharmacist for the most current availability status.


Q: Can older adults use Lolo?

Lolo is indicated for females of reproductive potential. Official documents state that the medication is not indicated for use in postmenopausal women (women who have stopped menstruating) as its purpose is contraception.


Q: Do I need to change my diet while taking Lolo?

Official labeling mentions that consuming grapefruit products may interact with the hormonal components, potentially leading to elevated plasma levels. Beyond this specific interaction, no broad dietary changes are typically mandated in the official prescribing information.


Q: What happens if I miss a day of Lolo?

Missing an active tablet may increase the risk of pregnancy due to the disruption of continuous hormone levels. Regulatory documents note that non-hormonal, back-up contraception is described as a required measure for seven consecutive days after missing an active dose.


Q: Does Lolo make you tired or sleepy?

Somnolence or fatigue are generally not listed among the common adverse events documented in the official prescribing information for this type of combined oral contraceptive. The most commonly reported side effects relate to gastrointestinal or menstrual changes.


Q: Is it common to have headaches when first starting Lolo?

Headache was reported as a common adverse event (7% incidence) in clinical trials. Official documents also note that side effects, including menstrual irregularities, are often more pronounced at the initiation of treatment but may lessen over the first few cycles.


Q: What does 'use conditions' for Lolo actually mean?

The term 'use conditions' refers to the specific, officially approved purposes (indications) for which the drug is prescribed (pregnancy prevention). It also includes the regulatory rules and requirements that define who can use the drug (eligibility) and how it must be taken.


Q: Is Lolo intended to be a cure for the condition?

Official labeling defines the primary purpose of Lolo as pregnancy prevention (contraception). It functions to manage fertility and is not defined as a treatment intended to cure a condition.


Q: Can Lolo cause stomach upset or nausea?

Nausea/Vomiting (7% incidence) and other Gastrointestinal effects, such as abdominal pain, are listed as frequently reported adverse reactions in official safety information. These effects are typically mild-to-moderate.


Q: Can Lolo be split or crushed?

Official administration instructions emphasize taking one whole tablet daily in a specific, sequential order. There is no official statement permitting the tablets to be split or crushed, which implies the integrity of the whole tablet is important for proper dosing.


Q: Are the side effects of Lolo permanent?

Clinical trial data notes that most reported side effects were considered mild-to-moderate and often diminished after the first few cycles of use. This observation suggests that the common, non-serious effects tend to be temporary.


Q: Can taking Lolo impact fertility (informational)?

Official literature on combined oral contraceptives indicates that normal fertility usually returns shortly after stopping the medication. The medication is described as a method of reversible fertility management.


Q: What kind of monitoring is recommended when on Lolo?

Regulatory guidance recommends measuring blood pressure before starting and periodically during use. Periodic assessment for changes in health status, such as new onset headaches or metabolic effects, is also advised by regulatory warnings.


Q: Is Lolo associated with hair loss?

Hair loss (alopecia) is not typically listed among the common adverse events in the official prescribing information for this type of combined oral contraceptive. Regulatory documents focus on effects observed in the largest clinical trials.


Q: Why is Lolo generally not recommended for children?

Lolo is indicated for females of reproductive potential. Official documents state that use of this product before menarche (the onset of menstruation) is not indicated due to a lack of data on efficacy and safety in this population.


Q: Does Lolo have any known interactions with herbal supplements?

The herbal supplement St. John’s wort (Hypericum perforatum) is officially associated with reduced contraceptive effectiveness due to its enzyme-inducing properties. This is the main herbal interaction listed in official labeling.


Q: Is it typical for Lolo to cause dry mouth?

Dry mouth is not listed among the commonly reported adverse events documented in the official prescribing information. The official documentation prioritizes the most frequently or seriously reported effects.


Q: What is the difference between an interaction and a contraindication for Lolo?

A contraindication is an absolute regulatory condition (like smoking over 35) that prohibits the use of the drug due to unacceptably high risk. An interaction is when a co-administered substance may change the effects of Lolo or vice-versa.


Q: How long until Lolo starts working?

Regulatory instructions for initiating therapy state that the body typically requires at least seven consecutive days of active pills to establish contraceptive protection. The official guidance indicates that a back-up method is described as a necessary measure during this initial period for certain starting methods.


Q: How are the side effects of Lolo classified in official documents?

Official documents classify side effects by their frequency of occurrence (e.g., common, uncommon, rare) and by the System Organ Class (e.g., Gastrointestinal disorders) they affect. This classification helps describe the safety profile of the medication.


Q: Is Lolo considered a high-risk drug by regulators?

Official labeling includes a Boxed Warning for serious cardiovascular risks, particularly in smokers over 35. This, along with extensive contraindications, signifies serious regulatory concern for use in certain high-risk populations.


Q: How long does the effect of Lolo last after taking it?

The product is prescribed on a once-daily, 24-hour cycle to maintain continuous, stable hormone levels in the body, which is necessary for the contraceptive effect. Missing a dose by more than 24 hours is associated with a potential reduction in contraceptive effectiveness.


Q: Can Lolo affect my blood pressure?

Official regulatory warnings state that combined oral contraceptives may increase blood pressure or worsen existing high blood pressure. Uncontrolled high blood pressure is listed as a contraindication for Lolo.

How should Lolo be stored and disposed of?

How to Store and Dispose of Lolo (Ethinyl Estradiol and Norethisterone Tablets)

The official labeling for Lolo mandates strict adherence to storage and disposal requirements to ensure product stability.

Storage Requirements

Condition Requirement (Official Statement)
Temperature Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Protection Keep the tablets in the original container and protected from moisture.
Safety Store the medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Lolo tablets must not be discarded in the household trash or flushed down the toilet (wastewater). Disposal should be carried out through an official drug take-back program or a community medicine collection site to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lolo found in:

A-Z Index: